Tactile Systems Technology, Inc. disclosed two directors’ pre-arranged stock-sale plans: William W. Burke adopted one on May 15, 2026 for up to 15,000 shares, and Laura G. King adopted one on May 18, 2026 for up to 6,000 shares.
TCMD · Tactile Systems Technology Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Tactile Systems Technology, Inc. added disclosures for Rule 10b5-1 plans adopted by William W. Burke and Kristie Burns during the quarter ended September 30, 2025, while making no changes to financial statements.
Tactile Systems Technology reported nine-month revenue of $252.8 million, up 12% from $225.9 million, and net income of $13.2 million, up 56% from $8.5 million for the periods ended September 30, 2026 and 2025.
Tactile Systems Technology, Inc. reported third-quarter revenue up 7% to $91.9 million, while net income declined to $7.2 million. It raised full year 2026 Adjusted EBITDA guidance to $50 million to $52 million from $49 million to $51 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 10, 2026TL;DR. Q2 revenue rose 9% to $85.7 million, gross margin expanded to 76.3%, net income increased 142% to $7.8 million, adjusted EBITDA increased 49% to $11.4 million, and lymphedema revenue rose 12%; the company launched next-generation AffloVest, secured MyoSleeve distribution rights, maintained $49 million to $51 million adjusted EBITDA guidance and expects low-double-digit lymphedema growth. AffloVest revenue fell 7%, Medicare prior authorization moderated Medicare orders, and the top end of 2026 revenue guidance declined from $368 million to $366 million amid DME inventory adjustments.
- + The company ended Q2 with $69.9 million in cash, no borrowings and $18.7 million remaining under its repurchase authorization.
- + The company maintained its full-year 2026 adjusted EBITDA outlook of $49 million to $51 million.
- + Six-month FlexiTouch head-and-neck trial results were published to support clinical adoption efforts.
- + LymphaTech submitted an expanded diagnostic-aid indication for lymphedema with FDA-expected approval in 2027.
- − Q2 airway-clearance revenue decreased 7% to $12.1 million due to elevated inventory at several large DME partners.
- − Q2 operating expenses increased 7% to $58.5 million as the company continued investing in growth initiatives.
- − Commercial payer coverage changes are not expected to occur immediately after the head-and-neck publication.
- − The Medicare prior-authorization requirement moderated Medicare order volumes during the quarter.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $15.1M | six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TCMD
this stock
Tactile Systems Technology Inc
|
$598.47M | -8.9% | +12.5% | 25.9 | 12.3% |
|
ABT
Abbott Laboratories
|
$180.95B | -16.6% | +5.7% | 39.0 | 1.1% |
|
MDT
Medtronic plc
|
$128.83B | +4.9% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$121.12B | -9.5% | +11.2% | 33.9 | 1.7% |
|
BSX
Boston Scientific Corp
|
$63.26B | -54.2% | +12.5% | 18.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 18
Tactile Systems Technology, Inc. added disclosures for Rule 10b5-1 plans adopted by William W. Burke and Kristie Burns during the quarter ended September 30, 2025, while making no changes to financial statements.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TCMD | -2.6% | +13.5% | +7.4% | +14.7% | -8.9% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +1.3% | +19.0% | +10.8% | +18.1% | -16.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.